Compare ARVN & NMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARVN | NMG |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Metals and Minerals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 516.2M | 414.7M |
| IPO Year | 2018 | 2015 |
| Metric | ARVN | NMG |
|---|---|---|
| Price | $9.20 | $1.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 2 |
| Target Price | ★ $15.05 | $5.75 |
| AVG Volume (30 Days) | ★ 878.8K | 423.1K |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.84 | N/A |
| EPS | ★ 1.70 | N/A |
| Revenue | ★ $262,600,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.28 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.96 | $1.26 |
| 52 Week High | $14.22 | $6.06 |
| Indicator | ARVN | NMG |
|---|---|---|
| Relative Strength Index (RSI) | 64.01 | 52.50 |
| Support Level | $7.90 | $1.39 |
| Resistance Level | $9.65 | $1.67 |
| Average True Range (ATR) | 0.40 | 0.07 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 75.50 | 76.82 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The Company currently operates in two segments: the Mining projects (which includes the Matawinie Mine project and the Uatnan Mining Project) and the Battery Material Plant project.